Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H15NO3 |
Molecular Weight | 317.338 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C3=CC=CC=C3
InChI
InChIKey=SLUINPGXGFUMLL-UHFFFAOYSA-N
InChI=1S/C20H15NO3/c22-19(17-8-4-5-9-18(17)20(23)24)21-16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13H,(H,21,22)(H,23,24)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22491093Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24928394
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22491093
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24928394
Kartogenin is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes. It is promising agent for treatment of osteoarthritis.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22491093
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map04350 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24928394 |
|||
Target ID: Q13951 Gene ID: 865.0 Gene Symbol: CBFB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26895619 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22491093
Sprague Dawley rats at 4 months of age were randomized into three groups: osteoarthritis (OA), kartogenin treatment (KGN), and control. On day 0, all the rats from OA and KGN group were anaesthetized with 2% isoflurane, a medial arthrotomy was performed and the anterior cruciate ligament was transected (ACLT) on the right knee. Postoperatively, 0.03mg/kg buprenorphine hydrochloride was administered by subcutaneous injection and as needed subsequently for pain control. Rats from KGN treatment group received weekly intra-articular injections of 125mM KGN in 50 ml of saline in the ACL transected knee joint.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24928394
Human dermal fibroblasts in vitro were treated with various concentrations of kartogenin, with dimethyl sulfoxide (DMSO) serving as the negative control. Real-time reverse-transcription PCT, Western blot, and immunofluorescence analyses were performed to examine the expression of collagen and transforming growth factor beta (TGF-β) signaling pathway.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID30385074
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
4727-31-5
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
2826191
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY | |||
|
Q93BBN11CP
Created by
admin on Sat Dec 16 09:29:34 GMT 2023 , Edited by admin on Sat Dec 16 09:29:34 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD